England’s National Health Service (NHS) now believes the competition brought about by biosimilars could save it up to £500m ($636m) annually within the next year or so. That figure is roughly double what the health system was forecasting barely 18 months ago, before a highly competitive, multisource market for adalimumab developed.
England Expects Biosimilar Savings Of Up To Half A Billion
With a tender and reference prices for adalimumab now in place, NHS England has raised its forecast for annual savings through biosimilar competition to half a billion pounds.
